Multi User License - $2,500
Nanomedicine is a field of medicine that employs nanotechnology’s knowledge and techniques to illness prevention and treatment. Nanotechnology is presently being used in the creation of novel medications in the European Union (EU), and it has been designated as a Key Enabling Technology capable of bringing new and creative medical solutions to address unmet medical needs.
Nanomedicine encompasses all nanotechnology and nanomaterials-related medical applications. The evaluation of the quality, safety, and efficacy of nanoscale materials prior to regulatory approval is a regulatory hurdle in nanomedicine.
The Europe Nanomedicine Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2026, registering a CAGR of XX% from 2022 to 2027.
The European Nanomedicine Map, created by the EU project NANOMED, gives comprehensive insights into the existing nanomedicine community by presenting all ecosystem actors in Europe and beyond on a single chart. This reference tool intends to raise awareness, provide new networking opportunities, and spark beneficial collaborations.
NANOMED MAP enlisted the help of Hypermorgen, a Berlin-based start-up, to work on the NanoMed Map’s design, implementation, and optimization. Because this feature was designed to be interactive and dynamic, all nanomedicine stakeholders are encouraged to explore the map and eventually update or add their entries.
EUNCL is a Horizon Framework Programme-funded European initiative that aims to perform and standardise pre-clinical characterisation of nanomaterials for medical purposes. The characterization platform developed by EUNCL seeks to examine all types of nanomedicines generated in the EU, in line with regulators’ desire for better analytical methodologies.
The EUNCL infrastructure promotes nanomedicine innovation by giving access to a state-of-the-art trans-disciplinary testing infrastructure for fully characterising nanomedicines generated by public labs, spin-offs, and innovative SMEs.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.